PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD-Reference-Cited by-同舟云学术

PK, PD, and interactions: the new scenario with JAK inhibitors and S1P receptor modulators, two classes of small molecule drugs, in IBD

Published:2020-07-01 Issue:9 Volume:14 Page:797-806
ISSN:1747-4124
Container-title:Expert Review of Gastroenterology & Hepatology
language:en
Short-container-title:Expert Review of Gastroenterology & Hepatology

Author:

Gilardi Daniela¹,Gabbiadini Roberto¹,Allocca Mariangela¹²,Correale Carmen¹,Fiorino Gionata¹²,Furfaro Federica¹,Zilli Alessandra¹,Peyrin-Biroulet Laurent³,Danese Silvio¹²^ORCID

Affiliation:

1. Humanitas Clinical and Research Center – IRCCS, Milan, Italy

2. Department of Biomedical Sciences, Humanitas University, Milan, Italy

3. Department of Gastroenterology and Inserm U954, Nancy University Hospital, Lorraine University, Vandoeuvre, France

Publisher

Informa UK Limited

Subject

Gastroenterology,Hepatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/17474124.2020.1785868

Reference97 articles.

1. Inflammatory Bowel Disease

2. Immunopathogenesis of IBD: current state of the art

3. Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management

4. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice

5. New biologics and small molecules in inflammatory bowel disease: an update

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis;Expert Opinion on Drug Metabolism & Toxicology;2024-09-12

2. Safety and Effectiveness of Thiopurines and Small Molecules in Elderly Patients with Inflammatory Bowel Diseases;Journal of Clinical Medicine;2024-08-09

3. Preventing and managing cardiovascular events in patients with inflammatory bowel diseases treated with small-molecule drugs, an international Delphi consensus;Digestive and Liver Disease;2024-08

4. Immunity in digestive diseases: new drugs for inflammatory bowel disease treatment—insights from Phase II and III trials;Journal of Gastroenterology;2024-07-09

5. Evaluating the pharmacokinetics of upadacitinib for the treatment of moderate-to-severe Crohn’s disease;Expert Opinion on Drug Metabolism & Toxicology;2024-05-03